Format

Send to

Choose Destination
Clin Pharmacol Ther. 2004 Jun;75(6):539-45.

Alpha 1A-adrenergic receptor polymorphism and vascular response.

Author information

1
Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

Abstract

OBJECTIVE:

The alpha(1A)-adrenergic receptor is highly expressed in human vasculature including resistance arteries and veins, and its stimulation is primarily responsible for adrenergically mediated smooth muscle contraction. Variability in sensitivity to phenylephrine, an alpha(1A) adrenergic agonist, has a large genetic component. We examined the hypothesis that a common polymorphism of alpha(1A)-adrenergic receptor (Arg347Cys) affects in vivo response.

METHODS:

We measured vascular sensitivity to phenylephrine using the dorsal hand vein linear variable differential transformer technique and determined alpha(1A)-adrenergic receptor genotype in 74 healthy, nonsmoking adults (28 Arg/Arg, 30 Arg/Cys, and 16 Cys/Cys).

RESULTS:

Sensitivity to phenylephrine, expressed as the dose of phenylephrine resulting in 50% venoconstriction (Phe(50)), was not significantly different in subjects with the 3 alpha(1A) adrenergic receptor genotypes: Phe(50) geometric mean (95% confidence interval) was 513 ng/min (287-918 ng/min) for Arg/Arg, 431 ng/min (274-680 ng/min) for Arg/Cys, and 471 ng/min (197-1124 ng/min) for Cys/Cys (P =.90).

CONCLUSION:

We conclude that the Arg347Cys receptor polymorphism does not alter agonist-mediated venoconstriction in vivo.

PMID:
15179408
DOI:
10.1016/j.clpt.2004.02.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center